Opinion|Videos|November 1, 2023

Available Treatment Options for Later Lines of Therapy in Patients With RRMM

Rafael Fonseca, MD, emphasizes the considerations of selecting therapies targeting specific markers like BCMA and GPRC5D in patients with relapsed/refractory multiple myeloma, such as prior exposures, efficacy, and potential side effects.


Latest CME